Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (331-340 of 345) with videos related to

Pageof 35
Sort By:
Annals of the Rheumatic Diseases|August 22, 2019
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, et al.
RMD Open|September 20, 2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationBrigitte Michelsen, Ulf Lindström, Catalin Codreanu, et al.
Seminars in Arthritis and Rheumatism|August 19, 2022
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationLykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|December 4, 2022
Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]Lykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|June 14, 2023
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registriesLouise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and responseSara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Nature|June 26, 2020
FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid diseaseSaedis Saevarsdottir, Thorunn A Olafsdottir, Erna V Ivarsdottir, et al.
Arthritis and Rheumatism|March 24, 2010
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapyJing Cui, Saedis Saevarsdottir, Brian Thomson, et al.
Pageof 35

Showing results (331-340 of 345) with videos related to

Sort By:
Pageof 35
Annals of the Rheumatic Diseases|August 22, 2019
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, et al.
RMD Open|September 20, 2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationBrigitte Michelsen, Ulf Lindström, Catalin Codreanu, et al.
Seminars in Arthritis and Rheumatism|August 19, 2022
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationLykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|December 4, 2022
Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]Lykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|June 14, 2023
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registriesLouise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and responseSara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Nature|June 26, 2020
FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid diseaseSaedis Saevarsdottir, Thorunn A Olafsdottir, Erna V Ivarsdottir, et al.
Arthritis and Rheumatism|March 24, 2010
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapyJing Cui, Saedis Saevarsdottir, Brian Thomson, et al.
Pageof 35